Citigroup Maintains Neutral on Biogen, Raises Price Target to $200

Benzinga Newsdesk www.benzinga.com Neutral 50.2%

Neg 0% Neu 50.2% Pos 0%

Citigroup analyst Geoff Meacham maintains Biogen (NASDAQ:BIIB) with a Neutral and raises the price target from $190 to $200.